Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NORDBIOTIC Gastro One BI040
- Development stage
- Preclinical
- Lead developer
- Nordic Biotic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
NORDBIOTIC Gastro One BI040 is a probiotic dietary supplement developed by Nordic Biotic, featuring the specific bacterial strain *Bifidobacterium lactis* BI040. Administered orally, it is designed to support gastrointestinal health by modulating the gut microbiome. Clinical studies have demonstrated its efficacy in the management of Irritable Bowel Syndrome (IBS), where it has shown significant reductions in IBS Severity Scoring System (IBS-SSS) scores, improved stool consistency, and relief from constipation and abdominal pain. The product has a clinically proven safety profile and has shown sustained symptomatic improvement in follow-up assessments.
- Brand names
- NORDBIOTIC Gastro One BI040
- Other names
- GASTRO ONE BI040Bifidobacterium lactis BI040
Beyond the preview
Go deeper on NORDBIOTIC Gastro One BI040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NORDBIOTIC Gastro One BI040.